I agree it's difficult to compare across studies, but I still am having a hard time reconciling the data as better than current options. This comes from their(Merrimack) Phase 2 paper.
"Results from one of the largest studies conducted to date for the second-line treatment of APC (CONKO-003) randomised 165 patients to receive a weekly regimen called OFF or 5-FU/folinic acid alone (Pelzer et al, 2008). Patients receiving the oxaliplatin-containing combination demonstrated significantly improved outcomes in terms of both progression-free survival (13 vs 9 weeks, P=0.012) and overall survival (26 vs 13 weeks, P=0.014), leading to the adoption of this regimen (or slight variations thereof) as a de facto standard of care in the salvage setting."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.